Comparative Pharmacology
Head-to-head clinical analysis: LEUPROLIDE ACETATE FOR DEPOT SUSPENSION versus LUPRON DEPOT PED KIT.
Head-to-head clinical analysis: LEUPROLIDE ACETATE FOR DEPOT SUSPENSION versus LUPRON DEPOT PED KIT.
LEUPROLIDE ACETATE FOR DEPOT SUSPENSION vs LUPRON DEPOT-PED KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leuprolide acetate is a synthetic gonadotropin-releasing hormone (GnRH) agonist. Continuous administration suppresses pituitary gonadotropin secretion, leading to decreased luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby reducing gonadal steroid production (testosterone and estrogen).
Leuprolide acetate, a GnRH agonist, initially stimulates pituitary gonadotropin release, but chronic administration suppresses LH and FSH secretion by downregulation of GnRH receptors, leading to reduced sex steroid production.
3.75 mg IM every 4 weeks or 11.25 mg IM every 12 weeks for advanced prostate cancer; 3.75 mg IM every month for endometriosis or uterine leiomyomas; 7.5 mg IM monthly for central precocious puberty.
Leuprolide acetate 3.75 mg IM monthly or 11.25 mg IM every 3 months; for central precocious puberty, 7.5 mg IM monthly or 22.5 mg IM every 3 months.
None Documented
None Documented
3-4 hours for subcutaneous injection; after depot injection, initial burst release followed by slow release with apparent half-life of approximately 3-4 weeks due to absorption rate-limited elimination.
Terminal elimination half-life is approximately 3 hours following subcutaneous administration; however, due to the depot formulation, the effective half-life is extended to about 1 month, driven by the slow release from the PLGA microspheres.
Primarily renal (metabolites), approximately 5% unchanged; fecal elimination accounts for <5%.
Renal (approximately 50% as unchanged drug and 50% as inactive metabolites); biliary/fecal excretion accounts for <5%
Category D/X
Category C
GnRH Agonist
GnRH Agonist